Breaking embargo: PREVAIL and how we publish data from clinical trials
This feature requires the newest version of Flash. You can download it here.
This media requires:
  • Javascript to be turned on
  • and one of the following:
  • An HTML5-compatible browser or
  • Adobe Flash Player version 8 and higher

April 12, 2013
Recorded: March 11, 2013

heartwire's Shelley Wood sits down with Drs Timothy Gardner, Cindy Grines, and Sanjay Kaul to talk about why PREVAIL was pulled from the late-breaking trial sessions, if it's appropriate for journalists and other parties to see data before physicians, and whether or not the existing embargo process needs to be fixed


Shelley Wood
Managing Editor,

Ms Wood has disclosed no relevant financial relationships.


Timothy Gardner MD
Past President, American Heart Association
Medical Director, Center for Heart and Vascular Health
Christiana Care Health System
Clinical Professor of Surgery, University of Pennsylvania School of Medicine
Wilmington, DE

Dr Gardner is chair of the steering committee of the Cardiothoracic Surgical Trials Network (NHLBI).

Cindy Grines MD
Vice President, Academic and Clinical Affairs
Detroit Medical Center-Cardiovascular Institute
Wayne State University
Detroit, MI

Dr Grines has served as an advisor or consultant for Abbott Vascular, Bristol-Myers Squibb, Merck, Lilly, the Medicines Company, and Volcano.

Sanjay Kaul MD
Attending cardiologist, Cedars-Sinai Medical Center
Professor, Geffen School of Medicine at UCLA
Los Angeles, CA

Dr Kaul has served as an advisor or consultant for the FDA and for Novo Nordisk. He owns stock, stock options, or bonds from Johnson & Johnson.

Related Links: